08.25.25 -- Clues To Mapping A Crisis-Ready Tech Transfer Playbook

In a recent webinar,  experts explored innovations, addressing production challenges, quality control strategies, and tech transfers to enhance scalability, efficiency, and global accessibility of gene therapies.

To ensure the success of gene therapy, learn why it is crucial to partner with a CRO that can navigate the challenges of viral vector development and testing.

Discover how the global expansion of ATMP trials offers significant advantages but demands early, strategic planning to overcome complex international challenges.

Achieving compliance and safety through Disinfectant Efficacy Studies (DES) is about adhering to regulations and committing to high standards of safety and quality of manufacturing operations.

Learn how precision fill/finish processes ensure the safety, sterility, and success of cutting-edge viral vector therapies as they move from production to patients.

Unlock the knowledge and strategies you need to navigate the complexities of CGT outsourcing and accelerate the success of your cell and gene therapy projects.

Explore how TARGATT® gene editing and HLA-F technologies are revolutionizing hypoimmunogenic cell development for scalable allogeneic therapies.

Consider these strategies for meeting quality and regulatory requirements in cell and gene therapies that can also help to identify issues early, reduce risks, and prevent delays and rework.

See how this advanced SKPT-HEK293 4G9 provided a robust solution for efficient viral vector production, supporting a range of AAV serotypes and CAR-T lenti-viral vectors for scalable manufacturing.

Extracellular vesicles hold immense potential for treating diseases, owing to their natural biocompatibility and ability to carry a diverse arsenal of therapeutic molecules.